Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new ...
On the basis of studies of the human dystrophin gene, one study predicts a 1 in 8 chance for deletions or 1 in 50 chance for duplications of a new variant arising de novo in an individual 113.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback